Non-Small Cell Lung Cancer Coverage from Every Angle
Editor:
David S. Ettinger, MD
Advertisement
Advertisement

Ongoing CE Activities

Proceedings from the 15th Annual Winter Lung Cancer Conference
Advanced Non-Small Cell Lung Ccancer Patient Management Simulator
An Advanced Practitioner’s Guide to Cell Signaling Pathways in NSCLC
Archived Monthly Oncology Tumor Boards: A Multidisciplinary Approach to Individualized Patient Care-Lung Cancer: Advanced Disease
ASTRO Issues New Guidelines on Stereotactic Radiation in Early NSCLC
Biomarker Analysis and the Implications for the Treatment of Non-Small Cell Lung Cancer
Case Studies in ALK-Translocated Advanced NSCLC: From Diagnosis to Treatment
Checkpoint Inhibitors in First-Line Advanced NSCLC: What Should You Know?
Clinical Challenges and Best Practices in Managing ALK-Positive NSCLC
Consensus or Controversy? Clinical Investigators Provide Perspectives on the Current and Future Role of Immune Checkpoint Inhibitors in the Management of Non-Small Cell Lung Cancer
Effects of Early Integrated Palliative Care on Caregivers of Patients with Lung and Gastrointestinal Cancer: A Randomized Clinical Trial
NCCN Pharmacy Updates: The Evolving Landscape of Immunotherapy and Targeted Therapy for Non–Small Cell Lung Cancer
EXPERT EXCHANGE: Management of Advanced EGFR Mutation-Positive NSCLC: Making Bold Strides Toward True Precision Medicine
Reflecting on Recent Evidence With an Eye to the Future of Lung Cancer Management
Immune Checkpoint Inhibitors in Lung Cancer: No Longer the Road Less Traveled?
The Evolving Landscape of Immunotherapy and Targeted Therapy for Non–Small Cell Lung Cancer
Immunotherapy in Advanced NSCLC: Will Combination Therapies Become Standard?
Improving Outcomes for Patients With Non–Small Cell Lung Cancer
Integrating Targeted Strategies in NSCLC
Integration of Immunotherapies Into the Treatment of Patients With Non–Small Cell Lung Cancer
JADPRO Regional Lectures: Immunotherapy: Case Studies in Non-Small Cell Lung Cancer
Lung Cancer series
Lung Cancer Update, Issue 2, 2017
Management of Advanced NSCLC: Where Do Immune Checkpoint Inhibitors Fit In?:
Minimizing the Impact of imAEs and Maximizing Efficacy: Pulmonary Toxicity
NCCN Continuing Education in Lung Cancer
NCCN Launches NCCN Congress Webinar Series™: Biomarkers 101
Oncology Grand Rounds Series: Part 1 — Non-Small Cell Lung Cancer: A satellite symposium held at the 2017 ONS Annual Congress
Oncology Grand Rounds: Non-Small Cell Lung Cancer
Optimizing Outcomes in Advanced NSCLC
Outcomes in NSCLC: A Focus on Quality Improvement - Part 1
Outcomes in NSCLC: A Focus on Quality Improvement - Part 2
PD-L1 Expression Testing
Cases from the Community: Clinical Investigators Provide Their Perspectives on Emerging Research and Actual Patients with Non-Small Cell Lung Cancer
Stage III NSCLC: Practical Application of Immune Checkpoint Inhibition After Chemoradiotherapy
Immuno-Oncology Therapy Essentials: Proactive Management of Immune-Related Adverse Events
Selecting Cancer Treatment: The Role of Tumor Molecular Profiling and Liquid Biopsy
Sustaining Change in Quality Improvement for NSCLC – Part 3
The Emerging Role of Molecular Testing in an Era of Precision Medicine - Non–Small Cell Lung Cancer
The Evolving Role of Biomarkers in Oncology
Treatment of EGFR-Mutated NSCLC: Assessing Your Clinical Practice
Tumor Mutation Burden Testing
Year in Review: Proceedings from the Multitumor Regional Symposium Focused on the Application of Emerging Research Information to the Care of Patients with Common Cancers
Copyright © 2019 National Comprehensive Cancer Network, All Rights Reserved
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.